Monoclonal Antibody Therapy in India
_____________________________
Schedule Consultation
Fill the form below and our medical team will contact you shortly.
Thank You!
Your enquiry has been submitted successfully.
Our team will contact you shortly.
Start Online Consultation
If you or your loved one has been diagnosed with cancer and is considering Monoclonal Antibody Therapy in India, an early specialist evaluation is essential. Fuda Cancer Centre offers expert online consultations for patients across India, allowing you to receive professional medical guidance without visiting the hospital initially.
Our experienced oncologist, Dr. Anup Aboti, will carefully review your biopsy reports, pathology findings, imaging scans (CT, MRI, or PET/CT), biomarker or genetic test results, previous treatments, and medical history to determine whether Monoclonal Antibody Therapy is an appropriate treatment option for your specific cancer. Based on a comprehensive evaluation, you will receive a personalized treatment plan and expert guidance for the next steps.
Start Online Consultation →Monoclonal Antibody Therapy is an advanced form of targeted cancer treatment that uses specially engineered antibodies to identify and attack specific proteins found on cancer cells. Patients across India can begin with an online consultation to receive an expert evaluation before treatment planning. This precision-based therapy helps target cancer cells while minimizing damage to many healthy tissues.
What Is Monoclonal Antibody Therapy?
Monoclonal Antibody Therapy is a type of targeted therapy that uses laboratory-produced antibodies designed to recognize specific proteins (antigens) on cancer cells. Once attached, these antibodies help the immune system identify and destroy cancer cells or block signals that promote tumor growth.
Treatment is recommended only after a comprehensive medical evaluation, including pathology review, imaging studies, and biomarker testing when appropriate.
Why Monoclonal Antibody Therapy Is Becoming an Important Cancer Treatment
- Targets specific cancer cells with precision
- Personalized treatment based on tumor biomarkers
- May improve treatment effectiveness in eligible patients
- Can be combined with chemotherapy, immunotherapy, or targeted therapy
- Used in both early-stage and advanced cancers depending on clinical indications
- Supported by evidence-based oncology guidelines
Monoclonal Antibody Therapy has become an important component of precision oncology for selected cancers where specific molecular targets are identified.
Who May Benefit from Monoclonal Antibody Therapy?
Eligibility depends on the type of cancer, biomarker or genetic testing results, previous treatments, and overall health. Specialists carefully review each patient's diagnosis before recommending therapy.
- Patients with biomarker-positive cancers
- HER2-positive breast or gastric cancer
- CD20-positive lymphoma
- EGFR-expressing colorectal or head and neck cancers
- Selected lung, ovarian, cervical, liver, and other solid tumors
- Patients receiving combination cancer treatment
Biomarker testing plays a key role in determining whether Monoclonal Antibody Therapy is likely to be effective.
Types of Cancer Commonly Treated
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Non-Hodgkin Lymphoma
- Leukemia
- Multiple Myeloma
- Head & Neck Cancer
- Stomach (Gastric) Cancer
- Ovarian Cancer
- Cervical Cancer
- Selected Liver Cancers
Treatment Process & Recovery
Before Treatment
- Review of biopsy and pathology reports
- CT, MRI, or PET/CT imaging
- Biomarker or genetic testing
- Comprehensive medical assessment
During Treatment
- Intravenous infusion under specialist supervision
- Monitoring for infusion-related reactions
- Supportive medications when indicated
Follow-Up Care
- Regular blood investigations
- Response assessment through imaging
- Monitoring for side effects
- Adjustment of future treatment cycles if required
Treatment schedules vary according to the specific monoclonal antibody, cancer type, and individual treatment goals.
Other Cancer Treatment Options
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Surgery
- Radiation Therapy
- Hormone Therapy
- Stem Cell Transplantation (selected blood cancers)
Many patients receive Monoclonal Antibody Therapy as part of a multidisciplinary treatment plan designed specifically for their cancer.
Treatment Comparison
| Treatment | Approach | Main Target | Clinical Use |
|---|---|---|---|
| Monoclonal Antibody Therapy | Targeted biological therapy | Specific proteins on cancer cells | Biomarker-positive cancers |
| Chemotherapy | Systemic drug therapy | Rapidly dividing cells | Many cancer types |
| Immunotherapy | Immune checkpoint activation | Immune system | Selected advanced cancers |
| Radiation Therapy | High-energy radiation | Localized tumors | Local disease control |
Choosing the Right Cancer Treatment Center
- Experienced medical oncology specialists
- Access to biomarker and molecular testing
- Multidisciplinary cancer care team
- Evidence-based treatment protocols
- Comprehensive follow-up and supportive care
How Indian Patients Can Get Started
Patients can share biopsy reports, pathology findings, imaging studies, biomarker test results, and previous treatment records through an online consultation. Specialists review every case individually and recommend whether Monoclonal Antibody Therapy is appropriate based on current clinical guidelines.
Benefits for Indian Patients
- Expert online consultation before hospital visit
- Personalized treatment recommendations
- Precision oncology based on biomarker testing
- Multidisciplinary cancer care
- Regular monitoring during treatment
- Long-term follow-up support
Monoclonal Antibody Therapy represents an important advancement in precision cancer treatment. When recommended for appropriate patients based on biomarker testing and clinical evaluation, it can become an effective component of a personalized cancer treatment plan under the supervision of experienced oncology specialists.
Alternative Treatments & When They May Be More Appropriate
Monoclonal Antibody Therapy is an important treatment option for many cancers, but it is not appropriate for every patient. Before recommending this therapy, oncologists evaluate the cancer type, stage, biomarker or genetic test results, previous treatments, overall health, and treatment goals to develop the most effective personalized care plan.
- Chemotherapy – Often recommended for cancers without suitable molecular targets or when rapid systemic treatment is required.
- Immunotherapy – May be preferred for cancers that respond well to immune checkpoint inhibitors.
- Targeted Therapy – Used when cancers have specific genetic mutations or molecular alterations.
- Surgery – Usually the preferred option for localized tumors that can be completely removed.
- Radiation Therapy – Commonly used for local tumor control, symptom relief, or as part of combined treatment.
- Hormone Therapy – Recommended for hormone-sensitive cancers such as certain breast and prostate cancers.
Many patients receive Monoclonal Antibody Therapy alongside other cancer treatments as part of a multidisciplinary treatment strategy.
Latest Advances in Monoclonal Antibody Therapy
Rapid advances in precision oncology continue to improve the effectiveness of Monoclonal Antibody Therapy. Better biomarker testing and newer antibody technologies allow doctors to select treatments that are more personalized for each patient.
- Improved biomarker and molecular testing for patient selection
- Development of next-generation monoclonal antibodies
- Growing use of antibody-drug conjugates (ADCs)
- Combination therapies with chemotherapy and immunotherapy
- Enhanced supportive care to reduce treatment-related side effects
- Ongoing clinical research in personalized cancer medicine
Current research focuses on improving long-term survival, reducing toxicity, and expanding treatment options for additional cancer types.
Key Differences: Side-by-Side
| Treatment | Main Purpose | Target Precision | Typical Use |
|---|---|---|---|
| Monoclonal Antibody Therapy | Targets specific cancer proteins | High | Biomarker-positive cancers |
| Chemotherapy | Destroys rapidly dividing cells | Low | Wide range of cancers |
| Immunotherapy | Activates the immune system | Moderate to High | Selected advanced cancers |
| Targeted Therapy | Blocks molecular growth pathways | High | Mutation-driven cancers |
Each treatment has a different mechanism of action. The most appropriate option depends on cancer type, molecular profile, stage, and the patient's overall clinical condition.
Treatment Cost & Ongoing Monitoring
The cost of Monoclonal Antibody Therapy varies according to the medication used, cancer type, treatment duration, and monitoring requirements. Regular follow-up is essential to evaluate treatment response and detect any potential side effects.
- Biomarker or genetic testing before treatment
- Intravenous infusion under medical supervision
- Routine blood investigations
- Periodic CT, MRI, or PET/CT imaging
- Monitoring for infusion-related reactions
- Long-term follow-up with oncology specialists
Patients should discuss expected treatment duration, monitoring schedules, and financial planning with their oncology care team before starting therapy.
Preparing for Monoclonal Antibody Therapy
Proper preparation helps improve treatment safety and effectiveness. Before starting therapy, specialists perform a detailed clinical assessment to confirm that the selected monoclonal antibody matches the patient's cancer characteristics.
- Review of biopsy and pathology reports
- Biomarker or molecular testing
- CT, MRI, or PET/CT scan evaluation
- Assessment of previous cancer treatments
- Routine blood tests and organ function assessment
- Discussion of possible benefits, risks, and expected outcomes
Patients should inform their healthcare team about allergies, previous infusion reactions, infections, and all current medications before treatment begins.
Long-Term Outcomes and Prognosis
Treatment outcomes vary according to the type of cancer, disease stage, biomarker expression, overall health, and response to therapy. When appropriately selected through biomarker testing, Monoclonal Antibody Therapy can become an important part of personalized cancer treatment.
- May improve disease control in eligible patients
- Can be combined with other cancer treatments
- Treatment response differs between cancer types
- Regular imaging helps monitor treatment effectiveness
- Long-term oncology follow-up remains essential
Your oncologist will discuss realistic treatment expectations based on your diagnosis, biomarker profile, imaging results, and current evidence-based clinical guidelines.
Why Choose Fuda Cancer Hospital for Monoclonal Antibody Therapy in India?
Expert medical oncology care, precision-targeted cancer treatment, and personalized support for patients across India.
Expert Evaluation by Medical Oncologists with Online Consultation for Indian Patients
Personalized Monoclonal Antibody Therapy Based on Biomarker Testing
Multidisciplinary Cancer Care for Comprehensive Treatment Planning
Advanced Precision Oncology for a Wide Range of Cancers
Structured Monitoring, Infusion Safety & Long-Term Follow-Up
Frequently Asked Questions – Monoclonal Antibody Therapy in India
Expert answers to common questions about Monoclonal Antibody Therapy, eligibility, biomarker testing, treatment process, safety, and personalized cancer care.
What is Monoclonal Antibody Therapy?
Monoclonal Antibody Therapy is a form of targeted cancer treatment that uses laboratory-produced antibodies to recognize specific proteins (antigens) on cancer cells. These antibodies help the immune system identify and destroy cancer cells or block signals that promote tumor growth. Treatment is recommended only after a detailed medical evaluation and biomarker testing when appropriate.
Which patients are eligible for Monoclonal Antibody Therapy?
Eligibility depends on the type of cancer, biomarker or genetic test results, stage of disease, previous treatments, and the patient's overall health. Medical oncologists carefully review pathology reports, imaging studies, and molecular testing before recommending Monoclonal Antibody Therapy.
Is Monoclonal Antibody Therapy the same as chemotherapy?
No. Monoclonal Antibody Therapy is different from conventional chemotherapy. It is a targeted biological therapy that focuses on specific proteins found on cancer cells, whereas chemotherapy affects rapidly dividing cells throughout the body. In many cases, Monoclonal Antibody Therapy may also be combined with chemotherapy or other cancer treatments.
How is Monoclonal Antibody Therapy administered?
Most monoclonal antibody medicines are administered through intravenous (IV) infusion in a hospital or specialized oncology center. The number of treatment sessions depends on the specific medication, cancer type, treatment response, and your oncologist's recommendations.
What are the possible side effects of Monoclonal Antibody Therapy?
Side effects vary depending on the medication used. Some patients may experience infusion-related reactions, fatigue, fever, chills, skin rash, diarrhea, or changes in blood test results. Your oncology team closely monitors treatment and provides supportive care to help manage side effects safely.
Which cancers can be treated with Monoclonal Antibody Therapy?
Monoclonal Antibody Therapy is used for several cancers, including breast cancer, colorectal cancer, lung cancer, lymphoma, leukemia, multiple myeloma, gastric cancer, ovarian cancer, cervical cancer, and selected biomarker-positive tumors. The treatment depends on whether the cancer expresses the appropriate molecular target.
Can Monoclonal Antibody Therapy be combined with other cancer treatments?
Yes. Depending on the diagnosis, Monoclonal Antibody Therapy may be combined with chemotherapy, immunotherapy, targeted therapy, hormone therapy, radiation therapy, or surgery. Your oncologist develops a personalized treatment plan based on current evidence-based oncology guidelines.
Why is biomarker testing important before treatment?
Biomarker or molecular testing helps determine whether your cancer has the specific target needed for Monoclonal Antibody Therapy to be effective. This precision medicine approach helps doctors select the most appropriate treatment while avoiding unnecessary therapies.
How can patients in India begin Monoclonal Antibody Therapy evaluation?
Patients can start with an online consultation by sharing biopsy reports, pathology findings, CT, MRI or PET/CT scans, biomarker test results, and previous treatment records. Oncology specialists review each case individually and recommend whether Monoclonal Antibody Therapy is suitable according to international treatment guidelines.
OUR ACHIEVEMENTS
Achievements of FUDA CANCER HOSPITAL
50+ Doctors
Professional Experts
1200+ Patients
Happy Indian Patients
100+ Countries
Global Presence
500+ Employees
Dedicated Workforce
Advanced Therapies for Cancer of All Stages
Nano Knife IRE (Irreversible Electroporation)
Cryotherapy | Cryosurgery | Cryo-ablation
Brachytherapy for Cancer
Microvascular Interventional Chemotherapy
Patient Testimonials
Mrs. Pratibha Rajgopal
Mrs. Dipikabehan Parmar
Mrs. Roseline Chandran
Mrs. Jyoti Bhatia